342 related articles for article (PubMed ID: 32916298)
21. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.
Al-Sanea MM; Gotina L; Mohamed MF; Grace Thomas Parambi D; Gomaa HAM; Mathew B; Youssif BGM; Alharbi KS; Elsayed ZM; Abdelgawad MA; Eldehna WM
Drug Des Devel Ther; 2020; 14():497-508. PubMed ID: 32103894
[TBL] [Abstract][Full Text] [Related]
22. Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity.
Chen X; Chen X; Steimbach RR; Wu T; Li H; Dan W; Shi P; Cao C; Li D; Miller AK; Qiu Z; Gao J; Zhu Y
Eur J Med Chem; 2020 Feb; 187():111950. PubMed ID: 31865013
[TBL] [Abstract][Full Text] [Related]
23. Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms.
Mehndiratta S; Chen MC; Chao YH; Lee CH; Liou JP; Lai MJ; Lee HY
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):74-84. PubMed ID: 33161799
[TBL] [Abstract][Full Text] [Related]
24. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
25. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of 2-quinolineacrylamides.
Wang SW; Lin MH; Hsu FC; Chen MC; Liou JP; Liu YT; Chen SS; Lee HY
Bioorg Med Chem; 2020 Feb; 28(3):115250. PubMed ID: 31924504
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
Xie R; Li Y; Tang P; Yuan Q
Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
[TBL] [Abstract][Full Text] [Related]
29. Novel 4-Oxoquinazoline-Based
Anh DT; Hai PT; Huy LD; Ngoc HB; Ngoc TTM; Dung DTM; Park EJ; Song IK; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
ACS Omega; 2021 Feb; 6(7):4907-4920. PubMed ID: 33644598
[TBL] [Abstract][Full Text] [Related]
30. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
[TBL] [Abstract][Full Text] [Related]
31. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors.
Mohamed MFA; Youssif BGM; Shaykoon MSA; Abdelrahman MH; Elsadek BEM; Aboraia AS; Abuo-Rahma GEA
Bioorg Chem; 2019 Oct; 91():103127. PubMed ID: 31374527
[TBL] [Abstract][Full Text] [Related]
32. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP
Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
Yao Y; Liao C; Li Z; Wang Z; Sun Q; Liu C; Yang Y; Tu Z; Jiang S
Eur J Med Chem; 2014 Oct; 86():639-52. PubMed ID: 25218912
[TBL] [Abstract][Full Text] [Related]
34. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J
Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities.
Ding J; Liu J; Zhang Z; Guo J; Cheng M; Wan Y; Wang R; Fang Y; Guan Z; Jin Y; Xie SS
Bioorg Chem; 2020 Aug; 101():104023. PubMed ID: 32650178
[TBL] [Abstract][Full Text] [Related]
37. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
Chao SW; Chen LC; Yu CC; Liu CY; Lin TE; Guh JH; Wang CY; Chen CY; Hsu KC; Huang WJ
Eur J Med Chem; 2018 Jan; 143():792-805. PubMed ID: 29223096
[TBL] [Abstract][Full Text] [Related]
38. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
[TBL] [Abstract][Full Text] [Related]
39. 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.
Huong TT; Dung do TM; Oanh DT; Lan TT; Dung PT; Loi VD; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB; Nam NH
Med Chem; 2015; 11(3):296-304. PubMed ID: 25256241
[TBL] [Abstract][Full Text] [Related]
40. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
